Tuesday, March 21, 2023
| Characteristic | V. alginolyticus | V. parahaemolyticus | V. cholerae non-O1/O139 | V. vulnificus | Other species |
|---|---|---|---|---|---|
| Total patients | 23 (100) | 20 (100) | 10 (100) | 7 (100) | 7 (100) |
| Demographics | |||||
| Age, y, median (SD) | 50 (+26.7) | 53 (+22.8) | 69 (+19.7) | 66 (+11.5) | 40 (+24.8) |
| Sex | |||||
| M | 19 (83) | 15 (75) | 7 (70) | 7 (100) | 6 (86) |
| F | 4 (17) | 5 (25) | 3 (30) | 0 | 1 (14) |
| Underlying condition | |||||
| Heart failure | 8 (35) | 6 (30) | 5 (50) | 4 (57) | 1 (14) |
| Neoplasia | 1 (4) | 5 (25) | 4 (40) | 0 (0) | 1 (14) |
| Diabetes | 2 (9) | 3 (15) | 1 (10) | 1 (14) | 1 (14) |
| Kidney failure | 2 (9) | 1 (5) | 1 (10) | 0 | 3 (43) |
| Immune disease | 2 (9) | 2 (10) | 1 (10) | 0 | 2 (29) |
| Hemopathy | 1 (4) | 1 (5) | 1 (10) | 1 (14) | 1 (14) |
| Liver disease | 1 (4) | 1 (5) | 2 (20) | 1 (14) | 0 |
| Alcohol use disorder | 2 (9) | 1 (5) | 2 (20) | 2 (29) | 0 |
| Preexisting wound | 3 (13) | 0 | 0 | 3 (43) | 0 |
| Digestive surgery | 2 (9) | 2 (10) | 1 (10) | 0 | 1 (14) |
| Time to symptom onset, d, median (SD) | 2.4 (+2.0) | 1.3 (+0.9) | 3 (+4.4) | 5.6 (+8.1) | 1 (+0.0) |
| Infection type | |||||
| Acute | 14 (61) | 19 (95) | 10 (100) | 7 (100) | 5 (71) |
| Chronic | 9 (39) | 1 (5) | 0 | 0 | 2 (29) |
| Outcome | |||||
| Recovered | 21 (91) | 17 (85) | 8 (80) | 6 (86) | 7 (100) |
| Died | 2 (9) | 3 (15) | 2 (20) | 1 (14) | 0 |
Table 1. Clinical characteristics of patients with Vibrio infection, by species, Bay of Biscay, France, 2001–2019*
*Values are no. (%) except as indicated.
| Antibiotic | V. alginolyticus | V. parahaemolyticus | V. cholerae non-O1/O139 | V. vulnificus | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | S | I | R | ||||
| Amoxicillin | 1 | 0 | 15 | 1 | 6 | 7 | 2 | 2 | 3 | 5 | 0 | 0 | |||
| Ticarcillin | 5 | 0 | 10 | 2 | 2 | 9 | 5 | 0 | 1 | 5 | 0 | 0 | |||
| First-generation cephalosporin | 10 | 4 | 0 | 13 | 1 | 0 | 4 | 1 | 0 | 4 | 1 | 0 | |||
Table 2. Available drug-susceptibility test results for the main antibiotics used to treat Vibrio infections, by species, Bay of Biscay, France, 2001–2019*
*Data are no. of cases. I, intermediate; R, resistant; S, susceptible.
| Characteristic | No sepsis, n = 42 | Septic shock, n = 13 | p value | ||||
|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | ||||
| Patient sex | |||||||
| M | 35 | 83 (72–95) | 10 | 77 (54–100) | 0.685 | ||
| F | 7 | 17 (5–28) | 3 | 23 (0.2–46) | |||
| Underlying conditions | |||||||
| Heart failure | 18 | 43 (28–58) | 6 | 46 (19–73) | Referent | ||
| Neoplasia | 6 | 14 (4–25) | 4 | 31 (6–56) | 0.223 | ||
| Diabetes | 7 | 17 (5–28) | 1 | 8 (0–22) | 0.664 | ||
| Kidney failure | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
| Immune disease | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
| Hemopathy | 3 | 7 (0–15) | 2 | 15 (0–35) | 0.582 | ||
| Liver disease | 2 | 5 (0–11) | 3 | 23 (0–46) | 0.318 | ||
| Alcohol use disorder | 3 | 7 (0–15) | 4 | 31 (6–56) | 0.102 | ||
| Preexisting wound | 6 | 14 (4–25) | 0 | 0 (0–0) | 0.317 | ||
| Digestive surgery | 4 | 10 (1–18) | 2 | 15 (0–35) | 0.618 | ||
| Species | |||||||
| V. alginolyticus | 10 | 24 (11–37) | 4 | 31 (6–56) | |||
| V. parahaemolyticus | 14 | 33 (19–48) | 5 | 38 (12–65) | |||
| V. cholerae non-O1/O139 | 8 | 19 (7–31) | 2 | 15 (0–35) | |||
| V. vulnificus | 6 | 14 (4–25) | 1 | 8 (0–22) | |||
| Other Vibrio species | 4 | 10 (1–18) | 1 | 8 (0–22) | |||
| Outcome | |||||||
| Recovered | 40 | 95 (89–100) | 7 | 54 (27–81) | 0.001 | ||
| Died | 2 | 5 (0–11) | 6 | 46 (19–73) | |||
Table 3. Clinical characteristics and outcome of patients with and without septic shock after acute Vibrio infection, Bay of Biscay, France, 2001–2019*
*Median patient age ( + SD) was 60 ( + 21.4) for no sepsis and 61 ( + 15.3) for septic shock.
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for primary care physicians, infectious disease specialists, and other clinicians who treat and manage patients who may become infected with Vibrio spp.
The goal of this activity is to assess the epidemiology, microbiology, and prognosis of infection with Vibrio spp.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 11/18/2022
Valid for credit through: 11/18/2023
processing....
Note: It is Medscape's policy to avoid the use of Brand names in accredited activities. However, in an effort to be as clear as possible, trade names are used in this activity to distinguish between different susceptibility tests. It is not meant to promote any particular product.
Noncholera vibriosis is a rare, opportunistic bacterial infection caused by Vibrio spp. other than V. cholerae O1/O139 and diagnosed mainly during the hot summer months in patients after seaside activities. Detailed knowledge of circulating pathogenic strains and heterogeneities in infection outcomes and disease dynamics may help in patient management. We conducted a multicenter case-series study documenting Vibrio infections in 67 patients from 8 hospitals in the Bay of Biscay, France, over a 19-year period. Infections were mainly caused by V. alginolyticus (34%), V. parahaemolyticus (30%), non-O1/O139 V. cholerae (15%), and V. vulnificus (10%). Drug-susceptibility testing revealed intermediate and resistant strains to penicillins and first-generation cephalosporins. The acute infections (e.g., those involving digestive disorder, cellulitis, osteitis, pneumonia, and endocarditis) led to a life-threatening event (septic shock), amputation, or death in 36% of patients. Physicians may need to add vibriosis to their list of infections to assess in patients with associated risk factors.
Some opportunistic pathogens associated with marine environments are already known but until now have caused rare infectious diseases. Among those pathogens are Vibrio spp. other than the well-known V. cholerae belonging to serogroups O1 and O139, which causes cholera. Vibrio spp. are gram negative, curved, rod-shaped bacteria that are natural inhabitants of the aquatic environment [1]. Vibrio infections can be very severe or even fatal; they cause gastroenteritis, severe bacterial cellulitis, or necrotizing fasciitis and can lead to septic shock. Infections are more common in patients with multiple underlying conditions, including liver disease, heart failure, diabetes, liver cirrhosis, alcohol abuse, and immunocompromising conditions [2–5]. Vibrio spp. can also cause mild diseases, such as chronic ear infections, which are more likely to affect younger patients [6]. Humans acquire Vibrio infections after eating contaminated raw seafood, especially oysters, or after exposing an injury to the marine environment [7]. Infections occur mainly during the hot summer months, which is probably attributable to higher water temperatures [8,9] and to increased seawater-related activities.
Because vibriosis is a relatively rare disease and is not reported in most national surveillance systems, the global incidence rate of Vibrio spp. infections other than V. cholerae O1/O139 is underestimated. In the United States, where those infections are notifiable, a marked seasonal distribution and an increasing incidence rate have been observed [10–12]. Because of their rarity, Vibrio infections are very poorly known and therefore probably underdiagnosed. Delays in therapeutic management and, in particular, in the prescription of a targeted antibiotic regimen have been documented [13]. Our study aimed to make an inventory of Vibrio infections diagnosed in hospitals in the Bay of Biscay on the west coast of France and to describe the clinical and epidemiologic characteristics of the patients and their therapeutic management.
